PDx
Contrast Media
Contrast Media are pharmaceutical formulations that allow for MRI and CT scan diagnosis to be more efficient and beneficial for medical decisions.
Pharmazac has been partnering since 1998 with the global pioneers in Contrast Media in order to bring to patients and in many territories pharmaceuticals that ensure a high-quality diagnosis. At the heart of this operational stands the long-term partnership with GE Healthcare on products for CT and MRI scans.
A dedicated business, sales and market team is focusing on analysing the trends and bringing to the hospitals and diagnostic centers state-of-the-art formulations. Moreover, Pharmazac has a long experience in the development, regulatory and quality assurance of Contrast Media and especially iodine-based products.


PDx
Nuclear Medicine
Nuclear medicine products are safe medical items containing tiny amounts of radioactive materialDoctors use them to find and treat illnesses deep inside the body. They show how organs work on a cell level, unlike normal X-rays that only show pictures of bones or tissue.
As a specialised category of products, it requires special logistics operations and customer service and handling; Pharmazac is operating a dedicated team of experts in Radiosafety and Marketing of Nuclear Medicine products.
In collaboration with large multinationals we bring in the Greek and other markets Generators, Cold kits and nuclear medicine products that serve the medical process and increase the accuracy and precision of the diagnosis.
PDx
Radiopharmaceuticals
Radiopharmaceuticals has been a new venture within the growing Pharmazac PDx division and was marked by the start of operations of a new state-of-the-art two (2) Cyclotrons facility in Lamia, Greece. This manufacturing site is dedicated on the production of pharmaceutical formulations with radioisotopes and offers innovative and highly reliable solutions for PET scan activities for Cancer, Brain Diseases and Cardiology.
We provide on a daily basis radiopharmaceutical to Hospitals, Private Diagnostic Centers and Clinics and offer then a reliable, high-quality product and service.
Pharmazac has partnered with GEHC, Bracco/ Blue Earth and other multi-nationals for manufacturing and promoting their 18F products while also running an ambitious R&D program in radiopharmaceutical. Our pipeline includes more than 7 launches between 2027 and 2032 making Pharmazac a dominant player in this market segment.


PDx
Theranostics
Theranostics are the future for cancer treatment and Pharmazac proudly joined a number of partnerships since 2024 in order to bring life-saving radiopharmaceutical that achieve cancer treatment where other options fail. A team of business development experts and a strong medical advising team are supporting the commercialisation of products based on the Lutetium (Lu) and Terbium (Tu) radioisotopes in Europe. The pipeline includes a series of launches in Greece and other countries starting from 2028 and aiming to develop a strong presence into this growing domain that saves human lives. Pharmazac is focusing on prostate cancer, breast cancer and pancreatic cancer as key directions for its current future directions.
PHARMAZAC
Recent Launches
